Clinical Trial Detail

NCT ID NCT03534323
Title Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Duvelisib + Venetoclax

Age Groups: adult senior

No variant requirements are available.